Your browser doesn't support javascript.
loading
Evaluating Aprepitant single-dose plus granisetron and dexamethasone in children receiving highly emetogenic chemotherapy for the prevention of chemotherapy-induced nausea and vomiting: A triple-blinded randomized clinical trial
Eghbali, Aziz; Kohpar, Fatemeh Khazaei; Ghaffari, Kazem; Afzal, Roghayeh Rahimi; Eghbali, Aygin; Ghasemi, Ali.
Affiliation
  • Eghbali, Aziz; Iran University of Medical Sciences. Clinical Research Development Center of Aliasghar Hospital. Tehran. IR
  • Kohpar, Fatemeh Khazaei; Arak University of Medical Sciences. Arak. IR
  • Ghaffari, Kazem; Khomein University of Medical Sciences. Department of Base and Laboratory Sciences. Khomein. IR
  • Afzal, Roghayeh Rahimi; Arak University of Medical Sciences. Arak. IR
  • Eghbali, Aygin; Iran University of Medical Sciences. Tehran. IR
  • Ghasemi, Ali; Semnan University of Medical Sciences. Department of Biochemistry and Hematology. Semnan. IR
Hematol., Transfus. Cell Ther. (Impr.) ; 45(3): 281-289, July-Sept. 2023. tab, graf
Article de En | LILACS | ID: biblio-1514162
Bibliothèque responsable: BR408.1
Localisation: BR408.1
ABSTRACT
ABSTRACT

Introduction:

This study was performed to evaluate the degree of 3-day chemotherapy-induced nausea and vomiting (CINV) in children with cancer who received highly emetogenic chemotherapy (HEC) to ascertain the efficacy of aprepitant single-dose on dayL 1 plus granisetron and dexamethasone (DEX).

Methods:

This clinical trial study was conducted on 120 patients in the age range of 5 to 18 years old who received chemotherapy. Patients were divided into two groups; Group A received aprepitant at 125 mg/kg on day 1 orally, followed by 80 mg/kg daily on days 2 and 3 and Group B received a single dose of aprepitant 125 mg/kg on day 1 orally and placebo on days 2 and 3. All groups received granisetron 3 mg/m2 on day 1 and DEX on days 1 to 3. The primary and secondary endpoints were to evaluate the proportion of patients with acute, delayed and overall CINV within each group.

Results:

There were no significant differences between the two groups for vomiting, nausea or the use of rescue therapy. The number of patients without vomiting on day 1 was similar in both groups (96.5% vs. 98.3%, respectively; p = 0.848).

Conclusion:

According to the results of this study, a single dose of aprepitant 125 mg/kg was as effective as administering three doses of aprepitant on 3 days. Therefore, the use of a single dose of aprepitant in combination with other standard treatment regimens to prevent CINV in children who received HEC was safe and efficacious and can be beneficial.
Sujet(s)
Mots clés

Texte intégral: 1 Indice: LILACS Sujet Principal: Vomissement / Dexaméthasone / Granisétron / Aprépitant / Nausée Limites du sujet: Adolescent / Child / Child, preschool / Humans langue: En Texte intégral: Hematol., Transfus. Cell Ther. (Impr.) Thème du journal: Hematologia / TransfusÆo de Sangue Année: 2023 Type: Article

Texte intégral: 1 Indice: LILACS Sujet Principal: Vomissement / Dexaméthasone / Granisétron / Aprépitant / Nausée Limites du sujet: Adolescent / Child / Child, preschool / Humans langue: En Texte intégral: Hematol., Transfus. Cell Ther. (Impr.) Thème du journal: Hematologia / TransfusÆo de Sangue Année: 2023 Type: Article